Discontinuation of Development of Anti-Diabetic Agent AJ-9677/TAK-677
OSAKA, JAPAN, --- Dainippon Pharmaceutical Co., Ltd. ("Dainippon") and Takeda Chemical Industries, Ltd. ("Takeda") today announced that it was decided to discontinue the development of β3-adrenaline receptor agonist, which was discovered by Dainippon and has been under clinical development. Development codes of Dainippon and Takeda are AJ-9677 and TAK-677 respectively.
In Japan, Dainippon has been conducting phase II studies with the patients of diabetes mellitus, while Takeda has been conducting phase II studies in the U.S. and Europe for diabetes mellitus and obesity. In 2000, Takeda was granted a development and marketing right by Dainippon for all the countries except Japan, South Korea, Taiwan and P.R. of China.
These clinical studies have not been able to show efficacy enough to further continue development of this agent, while there has been no safety concerns during the course of the studies.